For type 2 diabetes mellitus. Sold as Nesina. Every FDA application for this active ingredient: 1 branded and 2 generic.
As of Nov 15, 2026, FDA lists 3 applications for Alogliptin Benzoate (sold as Nesina), first approved Jan 25, 2013, with 2 new uses approved and 0 published complete response letters.
| Alogliptin | Part D | $12.7M | -14% | 15,683 |
| Nesina | Part D | $9K | -91% | 14 |
| Study | Phase | Status | Posted |
|---|---|---|---|
| Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes StudyCardiovascular Events, Type2 Diabetes · Brigham and Women's Hospital | — | Active, not recruiting | Feb 2, 2022 |
| Jan 25, 2013 | NesinaNDA 22271 · New molecular entity | Takeda Pharms USA | 12 | Marketed |
| — | AlogliptinANDA 210002 | Indoco Remedies | 0 | Discontinued |
| — | AlogliptinANDA 210213 | Msn Labs Pvt Ltd | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
